國藥一致(000028.SZ)業績快報:前三季度歸母淨利潤10.66億元 同比下降10.43%
格隆匯10月22日丨國藥一致(000028.SZ)公佈2024年度前三季度業績快報,2024年1-9月,公司實現營業收入564.66億元,同比下降0.21%;歸屬於上市公司股東的淨利潤10.66億元,同比下降10.43%,相應的基本每股收益同比下降10.75%,加權平均淨資產收益率同比下降1.19個百分點;扣除非經常性損益後的歸屬於上市公司股東的淨利潤10.24億元,同比下降10.39%。2024年第三季度,公司實現營業收入186.80億元,同比增長2.65%;歸屬上市公司股東的淨利潤3.22億元,同比下降10.39%。
2024年1-9月,分銷板塊實現營業收入408.36億元,同比增長3.20%;實現淨利潤7.81億元,同比下降0.91%。主要系應收賬款回款延遲,相應的資金成本增加,導致利潤下降。零售板塊(即“國藥控股國大藥房有限公司”)實現營業收入163.97億元,同比下降7.47%;實現淨利潤-0.39億元,同比下降110.36%。主要系受門診統籌等行業政策變化、市場競爭加劇等因素影響,零售板塊第三季度業績仍同比下滑,但隨着公司經營策略的調整,在經營團隊及各級員工的努力下,零售板塊的虧損面已逐步縮窄,第三季度實現淨利潤-2,467.93萬元,環比第二季度增加6,729.39萬元,增長率為73.17%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.